GTx Announces Presentation at the ASCO Genitourinary Cancers Symposium of Additional Study Results from the Phase III Clinical Trial Evaluating Toremifene 80 mg for the Reduction of Fractures in Men with Prostate Cancer on ADT

MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb 17, 2011 - GTx, Inc. (NASDAQ: GTXI) announced that additional study results from the Phase III clinical trial evaluating toremifene 80 mg for the reduction of fractures in men with prostate cancer on androgen deprivation therapy will be presented this afternoon at the 2011 ASCO Genitourinary Cancers Symposium being held in Orlando, Florida.

Poster presentation: "Factors associated with vertebral fractures in men treated with androgen-deprivation therapy (ADT) for prostate cancer."

 

  • Thursday, February 17, 2011 from 4:50 – 6:20 p.m.
  • General poster session B: Prostate cancer
  • Abstract number 205
  • Lead author: Saylor, P.J.

Poster presentation: "Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer."

 

  • Thursday, February 17, 2011 from 4:50 – 6:20 p.m.
  • General poster session B: Prostate cancer
  • Abstract number 212
  • Lead author: Morgans, A.K.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways for the treatment of cancer and the side effects of anticancer therapy, cancer supportive care, and other serious medical conditions.

 

Contact: GTx, Inc.
McDavid Stilwell, Director, Corporate Communications & Financial Analysis, 901-523-9700

 

 

Posted: February 2011

View comments

Hide
(web1)